ReviewJournal of biomedical science2026
The emerging pathogen Candida auris: host interactions and disease drivers.
Review in Journal of biomedical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Baicalein suppresses adhesion and biofilm formation inMicrobiology spectrum · 2026Article
- In Vitro Acid Resistance of Feline-DerivedJournal of fungi (Basel, Switzerland) · 2026Article
- Impact of COVID-19 and earthquake disaster on candidemia in the ICU: mortality and treatment outcomes.BMC infectious diseases · 2026Article
- Review
- Correction: The emerging pathogen Candida auris: host interactions and disease drivers.Journal of biomedical science · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
Candida auris has emerged over the past fifteen years as a multidrug-resistant human fungal pathogen responsible for hospital-acquired infections associated with high mortality rates. Clinical isolates frequently exhibit resistance to one or more first-line antifungal drugs, and management is further complicated by persistent colonization, biofilm formation, and historical misidentification in diagnostic laboratories. Rapid species-level identification and accurate antifungal susceptibility testing are critical for effective patient care and infection control. In this article, we summarize the clinical spectrum of C. auris infections, highlight key pathogenic traits and clade-specific biological differences, and discuss emerging diagnostic, therapeutic, and preventative strategies-including novel antifungal agents, host-directed therapies, and vaccine development-that may improve detection and expand treatment options for C. auris infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.